Welcome to our dedicated page for Hydreight Tech news (Ticker: HYDTF), a resource for investors and traders seeking the latest updates and insights on Hydreight Tech stock.
Hydreight Technologies Inc. reports on a U.S.-focused digital health infrastructure business that combines telehealth, pharmacy fulfillment, clinical coverage and on-demand healthcare services. Company news commonly covers financial results, platform operating leverage, product-order activity, partner onboarding and expansion of the VSDHOne direct-to-consumer platform.
Recurring developments also include new healthcare service categories, such as at-home STI pre-screening, updates on platform licenses and modular workflow capabilities, revenue guidance, profitability commentary and capital actions such as normal course issuer bid activity.
Hydreight Technologies (OTCQB: HYDTF, CSE: NURS) reported record Q2 2026 GAAP revenue of $28.0 million, up 421% from $5.4 million in Q2 2025, with Adjusted Revenue of $30.2 million. Gross profit was $5.4 million (up 182%), net income $2.5 million and Adjusted EBITDA $3.2 million.
Sequentially, revenue grew about 12.5% and gross profit about 7% versus Q1 2026. For the first half of 2026, revenue reached $53.0 million (up 434% year-over-year), net income $5.1 million and Adjusted EBITDA about $6.5 million. Virtual healthcare/direct-to-consumer revenue was approximately $22.8 million in Q2 and $42.7 million year‑to‑date, while pharmacy product sales were about $26.2 million in Q2.
Hydreight ended Q2 with $20.0 million in cash and $35.0 million in working capital and reaffirmed its 2026 revenue guidance of approximately $150 million.
Hydreight Technologies (OTCQB: HYDTF, TSXV: NURS) will release its Q2 2026 financial results after market close on Monday, August 31, 2026. Management will host an investor webcast and conference call on Tuesday, September 1, 2026 at 6:00 a.m. PT / 9:00 a.m. ET, featuring prepared remarks and live Q&A with research analysts.
CEO Shane Madden will lead discussion on business operations, VSDHOne platform growth, onboarding momentum, operating leverage, expansion into new healthcare verticals, pharmacy financing initiatives, and the company’s broader 2026 growth strategy. A replay of the webcast will be available after the event.
Hydreight Technologies (OTCQB: HYDTF, TSXV: NURS, FSE: SO6) will participate in Canaccord Genuity's 46th Annual Growth Conference, held August 11–13, 2026 at the InterContinental Boston. CEO Shane Madden and Board Chair Shafin Diamond Tejani will meet institutional investors to discuss operating progress and growth strategy.
According to Hydreight, recent highlights include record Q1 2026 revenue of $24.9 million (449% year-over-year growth), Adjusted EBITDA of $3.3 million, and $32 million in working capital. The VSDHOne ecosystem has expanded to more than 12,000 licenses, over 300 physicians, 3,000 nurses, nationwide pharmacy partnerships, and more than 45 physician-supervised healthcare products and programs.
Hydreight Technologies (OTCQB: HYDTF) provided a business update on its peptide healthcare platform following the July 23–24, 2026 meeting of the FDA’s Pharmacy Compounding Advisory Committee (PCAC). The committee recommended six peptide-related bulk drug substances (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) for potential inclusion on the Section 503A Bulks List, a step that is advisory only and does not constitute FDA approval.
According to Hydreight, peptide-based therapies are already a significant part of its physician-supervised, nationwide platform, which supports GLP-1 therapies, Sermorelin, Ipamorelin and other personalized treatments. The company reports more than 12,000 VSDHOne licenses sold (vs. approximately 3,000 at the end of 2025), a network of 300+ licensed physicians, over 3,000 licensed nurses, a pharmacy network covering all 50 U.S. states and more than 45 physician-supervised treatment offerings. Hydreight also highlights prior investments in clinical protocols, pharmacy relationships, proprietary technology and a strategic investment in Insu Therapeutics, stating these were driven by its long-term personalized medicine strategy rather than the recent PCAC recommendations.
Hydreight (OTCQB: HYDTF) refiled its condensed interim consolidated financial statements for the three months ended March 31, 2026 and 2025 on SEDAR+.
The refiling corrects revenue classification within segment disclosures in Note 16, but does not change total revenue, gross profit, net income, cash flows, or balance sheet amounts.
Hydreight (VSQTF) reported record Q1 2026 revenue of $24.9M, up 449% year-over-year, and non-GAAP Adjusted Revenue of $27.6M. Adjusted EBITDA reached about $3.3M with a 13.1% margin, and net income was $2.6M.
Hydreight ended the quarter with $24.2M in cash, $32.0M in working capital, and $36.4M in shareholders' equity. The platform now spans all 50 U.S. states with over 12,000 VSDHOne licenses sold and expanding pharmacy and strategic healthcare partnerships.
Hydreight Technologies (OTCQB: HYDTF) will release its Q1 2026 financial results after market close on Monday, June 1, 2026. Management will host an investor webcast and conference call on Tuesday, June 2, 2026 at 6:00 a.m. PT / 9:00 a.m. ET.
The webcast, led by CEO Shane Madden, will cover Q1 2026 results, business operations, VSDHOne platform growth, onboarding momentum, operating leverage, new healthcare verticals, pharmacy financing initiatives, and the company’s 2026 growth strategy and outlook. A replay will be available.
Hydreight (OTCQB:VSQTF) reported audited 2025 results: GAAP revenue $35.4M, Adjusted Revenue $43.56M, net income $1.69M and Adjusted EBITDA $2.54M. Cash improved to $15.65M at year-end and the company completed a $15M financing in January 2026. Platform scale: >11,000 VSDHOne licenses (Q1 2026: >12,000). Q4 revenue was $14.95M, reflecting accelerating adoption and improved operating leverage.
Hydreight (OTCQB: HYDTF; TSXV: NURS) announced a normal course issuer bid to repurchase up to 4,951,189 common shares, representing ~9.27% of issued shares and ~10.0% of the public float. The Bid runs from March 12, 2026 to March 11, 2027.
Purchases will be made on the Exchange at prevailing market prices through Research Capital Corporation and funded from existing working capital. The company said purchases aim to facilitate an orderly market and could be used if shares trade below perceived underlying value.
Hydreight Technologies (OTCQB: HYDTF) issued fiscal 2026 revenue guidance of approximately $150 million as a baseline “floor-case” and provided Q1 2026 revenue outlook of $25–$28 million. Management expects an Adjusted EBITDA margin of roughly 15–17% on this revenue assumption and assumes no material increase in fixed operating costs versus late 2025. The guidance excludes potential revenue from acquisitions, new markets, or commercial arrangements not operational as of Feb 2, 2026. Hydreight also completed a $15 million bought-deal financing to support working capital and transaction volume growth.